The global PCR technologies market is expected to grow from nearly $6.8 billion in 2013 to nearly $10.2 billion by 2018, an estimated compound annual growth rate (CAGR) of 8.5% from 2013 to 2018.
This report provides:
Download Report Overview
SCOPE AND FORMAT
The key PCR markets covered in the report are the markets for instruments, reagents, consumables and accessories, software and services, as well as PCR applications and technologies.
The PCR instruments market includes buffers and deoxynucleotide triphosphates [dNTPs] (buffers, contamination control kits, dNTP mixes), controls and cDNAs, primers (real-time PCR primers, human linkage mapping sets, mouse mapping primers), PCR enzymes and kits (contamination control kits, general PCR, fast PCR, multiplex PCR, wax beads for hot start PCR, high-fidelity PCR kits and other kits), accessories, reaction plates, adhesive films and thermal cyclers.
The other markets include reagents and consumables, and other accessories (PCR plates and frames, PCR tubes, PCR sealers and PCR plastics). The PCR software market includes primer design and sequencing software, PCR analyzer software, integrated software and others.
The PCR application market includes research (e.g., genetic testing, gene expression, genetic mapping, tissue typing, hybridization probes, DNA sequencing, the Human Genome Project, forensic science, DNA cloning, bioinformatics and others), diagnosis (a) infectious disease, for example, HIV, tuberculosis, spread of disease organisms, others, (b) cancer and (c) prenatal diagnosis and genetic abnormalities, and drug discovery.
The PCR technology market includes inverse PCR, in situ PCR, real-time PCR, reverse transcriptase PCR, nested PCR, long PCR, single cell PCR and others.
Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy where he focused on in-depth research; he also has worked at a large pharmaceutical company dealing with a wide range of medical therapeutics in early- and mid-stage drug development.
BIO087A - August 2011